J Forensic analysis
Price Targets (12m)
Detailed research
PART 1: TRADING EXECUTION
Trading Setup & Entry Strategy
The stock is currently in a BEARISH_DOWNTREND with a 20-day decline of -12.83%. While fundamentals remain solid (strong backlog, high-value consulting shift), technicals are broken.
- >Entry Zone: $106.50 – $108.50. This aligns with the lower Bollinger Band ($106.38) and provides a margin of safety before testing the previous consolidation lows.
- >Stop Loss: $103.50 (HARD). A break below the lower Bollinger Band area suggests an acceleration of the current downtrend.
- >Take Profit: $125.00 (Near 50-day SMA) and $139.00 (200-day SMA).
- >Position Sizing: Limit to 3% of portfolio due to negative momentum and current technical weakness.
PART 2: DETAILED RESEARCH
Recent Material Events (8-K Analysis)
Recent filings focus on the successful completion of the PA Consulting acquisition (March 20, 2026) and refinancing via new bonds and term loans. The integration of PA Consulting is currently driving significant SG&A costs, which is a temporary drag on margins but strategically critical for long-term growth in high-margin consulting.
Financial Health & Forensics
- >Revenue Quality: Revenue is solid, backed by a $19.0B backlog.
- [CRIT]Red Flags: Significant surge in SG&A expenses ($1.41B vs $1.04B YOY) due to non-deductible incentive comp and transaction costs.
- >Cash Flow: Operating cash flow is under pressure due to the $232.5M one-time payout for equity-based incentive grants related to the PA Consulting deal.
Technical Analysis & Trade Timing
- >Indicators: The stock is oversold with an RSI of 38.36. However, it is trading well below both the 50-day SMA ($125.74) and 200-day SMA ($139.68), signaling a clear Death Cross environment.
- >Reconciliation: While the fundamental growth story (AI data centers, life sciences) remains attractive, the technical picture is hazardous. Do not catch the knife. Use a limit order in the $106–$108 range to capture a potential mean reversion toward the 50-day SMA.
Investment Recommendation
HOLD / ACCUMULATE ON DIP. The company is fundamentally re-rating its business toward higher-margin consulting but is currently battling technical selling pressure. Maintain a disciplined, staggered entry approach.
One-Liner Thesis: Jacobs is in a transitional phase; long-term value is backed by a $19B backlog and AI-data center tailwinds, but the stock requires technical stabilization before establishing a full position.